VALERIO TX (ALVIO)

VALERIO THERAPEUTICS

Sell: €0.106|Buy: €0.11|Change: 0.00 (-2.75%)

Open

€0.11

Previous close

€0.109

Trade high

€0.11

Volume

137,108

Year high

€0.31

Year low

€0.0401

Dividend yield

–

Market capitalisation

€52.94 mn

P/E ratio

59.52

ISIN

FR0010095596

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA

Share price

Performance 23/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
VALERIO TX	+ 1.40
More...

Company profile

Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.